Literature DB >> 7066058

Rheumatoid factor inhibition of in vitro binding of IgG complexes in the human glomerulus.

W K Bolton, J H Schrock, J S Davis.   

Abstract

We studied the effects of rheumatoid factor (RF) on binding of immune complexes to activated C3 (C3b) receptors in vitro. IgM fraction of serum containing RF activity (IgM-RF), IgM isolated from pooled normal human serum and have no RF activity (IgM-control), bovine serum albumin, and Veronal buffered saline solutions were used in a C3b assay system consisting of aggregated human IgG (AggHuIgG) coupled to sheep erythrocytes (SRBC) with guinea pig and normal human serum complement. The number of glomerular bound AggHuIgG-SRBC with IgM-control and bovine serum albumin or Veronal buffered saline was similar, while the number of bound cells with IgM-RF was reduced significantly, This effect was seen with both guinea pig and normal human serum complements. Supernatant hemolytic complement activity was maintained with IgM-RF, but reduced with control solutions. The blocking factor was shown to be RF by serial dilutions of IgM-RF resulting in inverse correlations with latex flocculation and inhibition of SRBC binding, absorption of blocking from IgM-RF with insolubilized AggHuIgG, and failure of IgM-control to block binding. IgM-RF did not directly interfere with activation of complement, but blocked attachment of C3 to AggHuIgG and formation of C3b capable of reacting with glomerular receptors. These results showed that IgM-RF can inhibit binding of AggHuIgG complexes to human glomeruli. This in vitro phenomenon may represent a possible protective mechanism of RF in vivo in diseases with immuno complexes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7066058     DOI: 10.1002/art.1780250307

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Rheumatoid factor in patients with systemic lupus erythematosus.

Authors:  A Zoli; L Altomonte; R Caricchio; A Galossi; L Mirone; F Scuderi; M Magaro
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

2.  Determination of IgA- and IgM-rheumatoid factors in patients with rheumatoid arthritis with and without nephropathy.

Authors:  M Nakano; M Ueno; S Nishi; S Suzuki; H Hasegawa; T Watanabe; T Kuroda; S Ito; M Arakawa
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

3.  A role for rheumatoid factor enhancement of Plasmodium falciparum schizont inhibition in vitro.

Authors:  T J Green; B J Packer
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

4.  In situ immune complex formation in the mouse glomerulus: reactivity with human IgM rheumatoid factor and the effect on subsequent immune complex deposition.

Authors:  P M Ford; I Kosatka
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

5.  Superoxide generation by synovial fluid neutrophils enhanced by immune complexes and suppressed by rheumatoid factor in synovial fluid.

Authors:  T Todoroki; M Shingu; I Ezaki; M Nobunaga
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

6.  Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.

Authors:  G Doekes; J Schouten; A Cats; M R Daha
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

7.  Enzyme immunoassay of complement-binding rheumatoid factors.

Authors:  A M Teppo; C P Maury
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

8.  Rapidly progressive glomerulonephritis with glomerular crescent formation in rheumatoid arthritis.

Authors:  F C Breedveld; R M Valentijn; M L Westedt; J J Weening
Journal:  Clin Rheumatol       Date:  1985-09       Impact factor: 2.980

9.  Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA. Possible role of anti-idiotypic antibodies.

Authors:  B H Hahn; F M Ebling
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

10.  Rheumatoid factor in rheumatoid arthritis associated renal disease and in lupus nephritis.

Authors:  H Helin; M Korpela; J Mustonen; A Pasternack
Journal:  Ann Rheum Dis       Date:  1986-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.